Mina Mar Marketing – Blog & Announcements

HAARLEM, Netherlands and BELGRADE, Serbia, Feb 10, 2010 /PRNewswire via COMTEX/ — Slavica Biochem (http://www.slavicabiochem.com), registered subsidiary of Hard to Treat Diseases (http://www.htdsmedical.com) is pleased to announce that two members of its scientific team, Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer and Dr. Ivana Gadjanski, communication director, participated in the “Stem Cells and Neuroregeneration” Symposium, held in Haarlem, the Netherlands on Feb 5 – 6, 2010.

The Symposium was organized under the auspices of the European Cooperation in the Field of Scientific and Technical Research (COST), action B30 in which Dr Sanja Pekovic is a permanent member as a represenative of Serbia. Main topic of the Symposium was the potential therapeutical use of neural stem cells for neurodegenerative disorders. As summarized in the lecture by Dr. Zaal Kokaia, Professor of Neuroscience from the Stem Cell Centre, Lund, Sweden, the highest potential of successful stem cell therapy exists in spinal cord injury (SCI), amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s Disease), Parkinson’s disease (PD), multiple sclerosis (MS) and stroke.

This was an important event for HTDS, its research team and its management as the company continues to explore the options of commencing its own stem cell bank project together with the continuation of the due diligence stage with the potential merger candidates; engaged in the treatment of pre-term labor and induction of labor and other aspects of regenerative medicine.

Furthermore, very interesting was a lecture by Dr. Chris Airriess, “Towards an FDA approved trial for ES cell repair in spinal muscular atrophy”. Their work is currently in the pre-clinical development stage of stem cell based therapies for ALS, spinal muscular atrophy (SMA), spinal cord injury (SCI) and coronary heart disease. The end result they aim for is to perform the world’s first human embryonic stem cell therapy. A special focus during the Symposium was put on induced pluripotent stem cells and their potential clinical applications, by Dr. Sjef Copray, Associate Professor, Department Neuroscience, UMCG, Groningen, the Netherlands who was also one of the organizers of the Symposium. The lectures presented during the Symposium summarized recent advances in stem cell research and their future application in regenerative medicine, as well as the hurdles that still need to be overtaken before safe clinical application.

In other company events and news, as the company no longer subscribes to Pink Sheets filing services all company filings, non news worthy events, financial statements and similar will be posted on the companys own corporate web site www.htdsmedical.com and on its IR firms www.minamargroup.net web site (CLICK ON CLIENT SUPPORT TAB) or visit this direct link http://minamarmarketinggroup.helpserve.com/.

To be included in HTDS’ email database for press releases and industry updates, please subscribe at or opt in with your email address at this link: http://www.minamargroup.net/updates

BEIJING, Feb 10, 2010 /PRNewswire via COMTEX/ — RMD Entertainment Group’s (http://rmdmgroup.com/) China based subsidiary Innotrek Technology Co., Ltd. (http://www.innotrek.com/) has been awarded the “First Landscape Illumination Project” in Shanxi City for the Chinese Spring Festival.

After discussing its technological advantage with the city representatives, Innotrek Technology (RMDM) has been awarded this public illumination project in Shanxi as the company, as previously announced, starts offering new services in urban illumination.

Spring Festival/Chinese New Year represents the largest celebration in China, and preparations include illumination designs across public spaces. Projects awarded to Innotrek includes two city parks, main road surroundings and an overpass. The project’s mandate is to highlight the city’s ancient charm by the use of modern technology.

“Regarding this important project, Innotrek technology works closely with the Shuozhou Construction Bureau and Forestry and Park Development Bureau,” said Mr. Wynn Wang, RMDM’s CEO. He added, “We are thrilled to participate in a project that allows us to show our know-how, and present our company to the widest public possible. We are using the opportunity and deploying various marketing techniques to bring attention to Innotrek for other possible projects in other eligible cities; and highlighting the fact that Innotrek is an operating subsidiary of US based RMDM. The initial returns look very promising. We launched the preparations and the next step will be the discussion of the maintenance schedule further with the officials of Shanxi city. This is the first Spring Festival project for Shanxi, and needless to say, is also extremely important to Innotrek as well. This contract is a sizable one, and is one of many which Innotrek has placed a bid on, and or been selected for and or awarded. These and other contracts and projects will be announced on a timely basis. Innotrek is providing its full undivided attention to this task and putting out our best, to demonstrate our expertise and design abilities. In China this is very important, and we wish to rise to the occasion.”

In other news and updates; The company brings attention to Pink Sheet Filings filing of even date, where the images of the “First Landscape Illumination Project” in Shanxi City for the Chinese Spring Festival and the input of Innotrek Technology (RMDM) can be seen. The company also reminds its followers to monitor the Pink Sheets filings section, as the company will release some new and significant updates from its USA based operating subsidiary United Beverage Alliance this week.

The company intends to provide other further news and updates to its followers on a timely basis.

BELGRADE, Serbia, Feb 10, 2010 /PRNewswire via COMTEX/ — Hiru Corporation (HIRU; www.hirucorporation.com) and its European subsidiary MindUp BioResearch (www.mindupbioresearch.com) want to share publicly available information about the MindUp and Sabera Ruzdijic’s patents. Dr. Sabera Ruzdijic is the project and team manager of the MindUp BioResearch cancer project. The other team leaders in MindUp Research project are Dr. Nikola Tanic, Dr. Milica Pesicand and Dr. Jasna Bankovic.

The following links lead to the European Patent Office Database and patents awarded to Dr. Sabera Ruzdijic:

Link # 1 shows search results for “Sabera Ruzdijic” entered into European Patent Office’s “Advanced Search”, in the “Inventor(s)” field;

http://v3.espacenet.com/searchResults?DB=EPODOC&submitted=true&locale=en_EP&IN=Sabera%20Ruzdijic&ST=advanced&compact=false

Link # 2 shows the “Patent Family”, patents affiliated and similar to the MindUp Research patents,

http://v3.espacenet.com/searchResults?DB=EPODOC&submitted=true&locale=en_EP&IN=Sabera%20Ruzdijic&ST=advanced&compact=false

The patent invention relates to the field of cancer therapy, and more particularly to the use of antisense oligonucleotides to decrease up-regulated genes involved in lung and melanoma cancers. Treatment has the ability to reduce gene expression in lung cancer by more than 50%.

More updates will be released by the company shortly.

To be included in HIRU’s email database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.